vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $16.9M, roughly 1.4× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs 78.8%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $-69.4M). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs -10.8%).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
FVCB vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $23.0M |
| Net Profit | — | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | 43.7% | -428.9% |
| Net Margin | — | -416.2% |
| Revenue YoY | 4377.5% | 78.8% |
| Net Profit YoY | — | 25.7% |
| EPS (diluted) | $0.31 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | $23.0M | ||
| Q3 25 | $416.0K | $13.8M | ||
| Q2 25 | $15.8M | $14.2M | ||
| Q1 25 | $382.0K | $16.6M | ||
| Q4 24 | $378.0K | $12.9M | ||
| Q3 24 | $412.0K | $9.1M | ||
| Q2 24 | $415.0K | $7.0M | ||
| Q1 24 | $359.0K | $28.9M |
| Q4 25 | — | $-95.8M | ||
| Q3 25 | $5.6M | $-101.3M | ||
| Q2 25 | $5.7M | $-101.3M | ||
| Q1 25 | $5.2M | $-114.3M | ||
| Q4 24 | — | $-128.9M | ||
| Q3 24 | $4.7M | $-135.7M | ||
| Q2 24 | $4.2M | $-147.0M | ||
| Q1 24 | $1.3M | $-107.4M |
| Q4 25 | 43.7% | -428.9% | ||
| Q3 25 | — | -808.9% | ||
| Q2 25 | 45.9% | -772.2% | ||
| Q1 25 | — | -726.6% | ||
| Q4 24 | — | -1059.9% | ||
| Q3 24 | — | -1589.0% | ||
| Q2 24 | — | -1998.6% | ||
| Q1 24 | — | -394.0% |
| Q4 25 | — | -416.2% | ||
| Q3 25 | 1341.1% | -735.2% | ||
| Q2 25 | 36.0% | -710.8% | ||
| Q1 25 | 1352.1% | -687.6% | ||
| Q4 24 | — | -1001.2% | ||
| Q3 24 | 1133.3% | -1489.5% | ||
| Q2 24 | 1001.2% | -2112.6% | ||
| Q1 24 | 373.3% | -371.3% |
| Q4 25 | $0.31 | $-0.81 | ||
| Q3 25 | $0.31 | $-0.92 | ||
| Q2 25 | $0.31 | $-0.98 | ||
| Q1 25 | $0.28 | $-1.10 | ||
| Q4 24 | $0.27 | $-1.27 | ||
| Q3 24 | $0.25 | $-1.34 | ||
| Q2 24 | $0.23 | $-1.52 | ||
| Q1 24 | $0.07 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $253.6M | $671.4M |
| Total Assets | $2.3B | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $449.9M | ||
| Q3 25 | — | $511.0M | ||
| Q2 25 | — | $459.7M | ||
| Q1 25 | — | $503.7M | ||
| Q4 24 | — | $601.5M | ||
| Q3 24 | — | $658.1M | ||
| Q2 24 | — | $691.1M | ||
| Q1 24 | — | $791.3M |
| Q4 25 | $253.6M | $671.4M | ||
| Q3 25 | $249.8M | $748.4M | ||
| Q2 25 | $243.2M | $715.3M | ||
| Q1 25 | $242.3M | $779.9M | ||
| Q4 24 | $235.4M | $872.0M | ||
| Q3 24 | $230.8M | $962.6M | ||
| Q2 24 | $226.5M | $971.1M | ||
| Q1 24 | $220.7M | $1.0B |
| Q4 25 | $2.3B | $842.1M | ||
| Q3 25 | $2.3B | $925.3M | ||
| Q2 25 | $2.2B | $898.9M | ||
| Q1 25 | $2.2B | $986.2M | ||
| Q4 24 | $2.2B | $1.2B | ||
| Q3 24 | $2.3B | $1.2B | ||
| Q2 24 | $2.3B | $1.2B | ||
| Q1 24 | $2.2B | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $-69.3M |
| Free Cash FlowOCF − Capex | $23.8M | $-69.4M |
| FCF MarginFCF / Revenue | 140.7% | -301.6% |
| Capex IntensityCapex / Revenue | 0.3% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | $-69.3M | ||
| Q3 25 | $7.6M | $-76.9M | ||
| Q2 25 | $3.3M | $-99.6M | ||
| Q1 25 | $5.4M | $-148.9M | ||
| Q4 24 | $18.2M | $-85.2M | ||
| Q3 24 | $4.7M | $-84.8M | ||
| Q2 24 | $1.6M | $-58.2M | ||
| Q1 24 | $7.2M | $-120.7M |
| Q4 25 | $23.8M | $-69.4M | ||
| Q3 25 | $7.6M | $-76.9M | ||
| Q2 25 | $3.3M | $-99.9M | ||
| Q1 25 | $5.4M | $-149.7M | ||
| Q4 24 | $18.1M | $-86.2M | ||
| Q3 24 | $4.6M | $-86.1M | ||
| Q2 24 | $1.5M | $-59.2M | ||
| Q1 24 | $7.1M | $-123.2M |
| Q4 25 | 140.7% | -301.6% | ||
| Q3 25 | 1818.0% | -558.2% | ||
| Q2 25 | 20.8% | -701.0% | ||
| Q1 25 | 1413.6% | -900.1% | ||
| Q4 24 | 4786.0% | -669.4% | ||
| Q3 24 | 1121.8% | -945.2% | ||
| Q2 24 | 361.2% | -850.9% | ||
| Q1 24 | 1988.3% | -425.7% |
| Q4 25 | 0.3% | 0.5% | ||
| Q3 25 | 0.2% | 0.2% | ||
| Q2 25 | 0.1% | 1.7% | ||
| Q1 25 | 4.2% | 4.4% | ||
| Q4 24 | 37.3% | 7.6% | ||
| Q3 24 | 14.1% | 14.0% | ||
| Q2 24 | 12.8% | 14.5% | ||
| Q1 24 | 3.9% | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVCB
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
